Drug Trial Radar · NCT04663282
A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics
Last checked: Nov 19, 2026Latest source record: Dec 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
179
Actual
Start
Feb 4, 2021
Primary completion
May 28, 2022
Study completion May 28, 2022
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the efficacy and safety of IND068 once daily (QD) in subjects with type 2 diabetes not adequately controlled with one or two oral antidiabetics compared to insulin degludec QD for 16 weeks.
Conditions
- Type 2 Diabetes
Interventions
INS068 injectionDrug
INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial
Insulin DegludecDrug
Insulin Degludec injected subcutaneously once daily. Treat-to-target dose titration during the trial
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1cTime frame: Week 0 to Week 16
Locations
35 sites in 3 countries. Site status is shown where the registry gives one.
National Research Institute - Huntington Park
Huntington Park, California
Clinical Trials Research
Lincoln, California
Torrance Clinical Research Institute Inc
Lomita, California
National Research Institute - Wilshire
Los Angeles, California
ALL Medical Research, LLC
Cooper City, Florida
New Generation of Medical Research
Hialeah, Florida
Clinical Pharmacology of Miami, LLC
Miami, Florida
Progressive Medical Research
Port Orange, Florida
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa
Endocrinology Associates, Inc
Columbus, Ohio
Prestige Clinical Research
Franklin, Ohio
Juno Research, LL
Houston, Texas
Juno Research, LLC - Medical Center Office
Houston, Texas
Juno Research, LLC - Southwest Houston Site
Houston, Texas
Endeavor Clinical Trials
San Antonio, Texas
Core Research Group Pty Ltd
Brisbane, Queensland, Australia
The Royal Melbourne Hospital
Melbourne, Victoria, Australia
Austin Health (Heidelberg Repatriation Hospital)
Melbourne, Victoria, Australia
Peking University People's Hospital
Beijing, Beijing Municipality, China
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Chongqing University Three Gorges Hospital
Chongqing, Chongqing Municipality, China
Hainan General Hospital
Haikou, Hainan, China
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Tongji Hospital of Tongji Medical College, Huazhong University of Scince and Technology
Wuhan, Hubei, China
Nanjing Drum Tower Hospital,The Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China
Zhongda Hospital Affiliated to Southeast University
Nanjing, Jiangsu, China
Jiangxi Provincial People's Hospital
Nanchang, Jiangxi, China
Shengjing Hospital Of China Medical University
Shenyang, Liaoning, China
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
Shanghai Xuhui District Central Hospital
Shanghai, Shanghai Municipality, China
Shanghai Putuo District Central Hospital
Shanghai, Shanghai Municipality, China
First Hospital of Shanxi Medical University
Taiyuan, Shanxi, China
West China Hospital,Sichuan University
Chengdu, Sichuan, China
Yibin Second People's Hospital
Yibin, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.